Contineum Therapeutics, Inc. (CTNM)

Contineum Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022
Cash & Equivalents	15.53	5.57
Short-Term Investments	109.66	41.67
Cash & Cash Equivalents	125.19	47.24
Cash Growth	165.01%	-
Other Current Assets	2.52	1.15
Total Current Assets	127.71	48.39
Property, Plant & Equipment	1.4	2.12
Other Long-Term Assets	1.28	0.13
Total Long-Term Assets	2.68	2.24
Total Assets	130.39	50.64
Accounts Payable	0.64	0.43
Current Debt	0.46	5.06
Other Current Liabilities	4.39	2.06
Total Current Liabilities	5.48	7.55
Long-Term Debt	0.11	0.79
Other Long-Term Liabilities	0.11	3.03
Total Long-Term Liabilities	0.22	3.82
Total Liabilities	5.7	11.37
Total Debt	0.57	5.85
Debt Growth	-90.22%	-
Retained Earnings	-75.14	-97.86
Comprehensive Income	0.11	-0.08
Shareholders' Equity	-67.94	-93.21
Net Cash / Debt	124.62	41.39
Net Cash / Debt Growth	201.08%	-
Net Cash Per Share	36.70	18.45
Working Capital	122.22	40.84
Book Value Per Share	-29.42	-41.56

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).